Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Journal Article Hematology · December 2025 INTRODUCTION: Chronic myeloid leukemia in the chronic phase (CML-CP) has undergone therapeutic transformation with the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), improving 10-year survival rates from 20% to ∼90%. These outcomes place increasing ... Full text Link to item CiteMastocytosis: Part I: Pathogenesis, Clinical Presentation and Classification.
Journal Article J Am Acad Dermatol · June 19, 2025 Mast cells are tissue-resident immune cells which secrete numerous and varied immune mediators in response to a myriad of activation pathways and play an important physiological function in immunity, homeostasis, tissue repair, and nervous system regulatio ... Full text Link to item CiteMastocytosis: Part II: Diagnosis and Management of Mastocytosis through a Multidisciplinary Lens.
Journal Article J Am Acad Dermatol · June 19, 2025 Mastocytosis is a heterogeneous disorder marked by mast cell accumulation in various organs, presenting differently in children and adults. Red or brown maculopapular lesions on the skin should raise suspicion for mastocytosis. In children, presentations i ... Full text Link to item CiteRecent Grants
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low
Clinical TrialPrincipal Investigator · Awarded by PharmaEssentia Corporation · 2025 - 2030A Phase 2a, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants with Polycythemia Vera (PV
Clinical TrialPrincipal Investigator · Awarded by Disc Medicine Inc. · 2025 - 2030A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2025 - 2030View All Grants
Education, Training & Certifications
University of North Dakota, School of Medicine and Health Sciences ·
2008
M.D.